Hospira (FRA:HOS) Cost of Goods Sold : €2,353 Mil (TTM As of Jun. 2015)

View and export this data going back to . Start your Free Trial

What is Hospira Cost of Goods Sold?

Hospira's cost of goods sold for the three months ended in Jun. 2015 was €592 Mil. Its cost of goods sold for the trailing twelve months (TTM) ended in Jun. 2015 was €2,353 Mil.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Hospira's Gross Margin % for the three months ended in Jun. 2015 was 43.88%.

Cost of Goods Sold is also directly linked to Inventory Turnover. Hospira's Inventory Turnover for the three months ended in Jun. 2015 was 0.54.

Hospira Cost of Goods Sold Historical Data

The historical data trend for Hospira's Cost of Goods Sold can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hospira Cost of Goods Sold Chart

Hospira Annual Data

Trend

Dec05

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Cost of Goods Sold

Get a 7-Day Free Trial

1,816.52

2,021.22

2,269.77

2,133.28

2,333.41

Hospira Quarterly Data
	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15
Cost of Goods Sold	Get a 7-Day Free Trial															541.55	558.18	600.87	601.89	591.80

Hospira Cost of Goods Sold Calculation

Cost of Goods Sold is the aggregate cost of goods produced and sold, and services rendered during the reporting period. It excludes Total Operating Expense, such as Depreciation, Depletion and Amortization and Selling, General, & Admin. Expense.

Cost of Goods Sold for the trailing twelve months (TTM) ended in Jun. 2015 adds up the quarterly data reported by the company within the most recent 12 months, which was €2,353 Mil.

Hospira (FRA:HOS) Cost of Goods Sold Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Hospira's Gross Margin % for the three months ended in Jun. 2015 is calculated as:

Gross Margin %	=	(Revenue	-	Cost of Goods Sold)	/	Revenue
	=	(1054.588	-	591.803)	/	1054.588
	=	43.88 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Cost of Goods Sold is also directly linked to another concept called Inventory Turnover:

Hospira's Inventory Turnover for the three months ended in Jun. 2015 is calculated as:

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	591.803	/	1090.201
	=	0.54

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher inventory turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate inventory turnover. An average inventory is a better indication.

Hospira Cost of Goods Sold Related Terms

Thank you for viewing the detailed overview of Hospira's Cost of Goods Sold provided by GuruFocus.com. Please click on the following links to see related term pages.

Hospira (FRA:HOS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hospira Inc (FRA:HOS) » Definitions » Cost of Goods Sold

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.hospira.com

Hospira Inc was incorporated in Delaware on September 16, 2003.Â The Company is a provider of injectable drugs and infusion technologies, and is also engaged in developing, manufacturing, marketing and distribution. Its portfolio includes generic acute-care and oncology injectables, biosimilars, and integrated infusion therapy and medication management products. Its portfolio of products is used by hospitals and alternate site providers, such as clinics, home healthcare providers and long-term care facilities. The Company's business segments are Specialty Injectable Pharmaceuticals, Medication Management and Other Pharmaceuticals. Specialty Injectable Pharmaceuticals consists of generic injectable pharmaceuticals products. Generic injectable pharmaceuticals provide customers with a lower-cost alternative to branded products when associated patent protection expires, when patents are declared invalid, or when the generic products do not infringe the patents of others. Our generic injectable pharmaceuticals are sold in therapeutic areas including analgesia, anesthesia, anti-infectives, cardiovascular, oncology, and other. Medication Management offer the Hospira MedNet safety software system, which is designed for hospitals to customize intravenous drug dosage limits and track drug delivery to prevent medication errors. The wireless network version of the Hospira MedNet system establishes real-time send-and-receive capability and can interface with select hospital and pharmacy information systems. Other Pharmaceuticals primarily consists of large volume I.V. solutions, nutritionals and contract manufacturing services. We offer infusion therapy solutions and related supplies that include I.V. solutions for general use, I.V. nutrition products, and solutions for washing and cleansing of wounds or surgical sites. The Company's primary customers include hospitals, wholesalers, integrated delivery networks and alternate site facilities. Its competitors include Baxter International Inc.; Becton, Dickinson and Company; Fresenius Kabi AG; Mallinckrodt plc; Mylan Inc; Par Pharmaceuticals Companies, Inc.; Pfizer Inc.; Sandoz; Sanofi S.A. and Teva Pharmaceuticals, Aspen Medical; Fresenius Kabi; Pfizer; Sandoz and a number of smaller competitors and the originator companies. The Company's operations and business activities are subject to extensive legal and regulatory requirements that are enforced by numerous governmental agencies in the countries in which it do business.

Hospira (FRA:HOS) Headlines

No Headlines